Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 91Neoplasms 75Prostatic Neoplasms 54Carcinoma, Hepatocellular 53Colorectal Neoplasms 49Leukemia, Myeloid, Acute 41Stomach Neoplasms 36Carcinoma, Non-Small-Cell Lung 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 29Pancreatic Neoplasms 27Lung Neoplasms 26Rectal Neoplasms 23Multiple Myeloma 21Hematologic Neoplasms 21Head and Neck Neoplasms 20Colonic Neoplasms 20Recurrence 19Lymphoma 19Leukemia 19Polycystic Ovary Syndrome 16Liver Neoplasms 14Esophageal Neoplasms 14Brain Neoplasms 13Myelodysplastic Syndromes 12Melanoma 12Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Motor Activity 11Fatigue 11

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Castration-resistant Prostate Cancer Patients with Oligometastases × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡